Tesamorelin and the visceral-fat problem Tesamorelin is one of the most relevant therapies in body recomposition when central fat and visceral adiposity are a major part of the problem
Verrastro O, Panunzi S, Castagneto-Gissey L, et al
Document the exposure circumstances, including approximate temperature, duration of exposure, and any changes in the medication's appearance
The current medical consensus, reflected in obesity medicine guidelines from organizations such as the American Gastroenterological Association and Obesity Medicine Association, treats obesity as a chronic disease requiring long-term pharmacological management in most cases, similar to hypertension or hyperlipidemia
received funding from Novo Nordisk, Eli Lilly, Merck, Structure Therapeutics and Prostasis